CureVac (CVAC) 6-K CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of August 2024

Commission File Number: 001-39446

CureVac N.V.

(Exact Name of Registrant as Specified in Its Charter)

Friedrich-Miescher-Strasse 15, 72076

Tübingen, Germany

+49 7071 9883 0

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form 40-F ¨

On August 15, 2024, CureVac N.V. (the “Company”) issued a press release announcing the appointment of Dr. Mehdi Shahidi as an independent director to the company’s Supervisory Board.

The information included in this Form 6-K (including Exhibit 99.1, but excluding the statements of the Chairman of the Company’s Supervisory Board and Dr. Shahadi contained in Exhibit 99.1 hereto) is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-259613).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CUREVAC N.V.
By:	/s/ Alexander Zehnder
	Chief Executive Officer

Date: August 15, 2024

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	CureVac N.V. Press Release dated August 15, 2024